Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

new long acting formulation of an old dependable drug

April 28, 2009

Analysis of:RISPERDAL(R) CONSTA(R) Approved in Japan | www.pipelinereview.com

Risperdal has been a good drug for schizophrenia, a most challenging disease for a long time. Other drugs have come along but none have really been found superior in efficacy or side effect profile. The benefit of a long acting formulation is that outpatient care is made easier , reducing compliance issues and therefore controlling the disease far more likely. It is very helpful to be able to have another choice in the armentarium of a drug that doctors know and trust.

No need to lag as the day goes on for sleep apnea, narcolepsy and jet laggers

April 16, 2009

Analysis of:Cephalon to apply for FDA approval for Nuvigil for jet lag | www.reuters.com

An FDA approved alternative to modafinal will soon be available that will allow patients who suffer from sleepiness during the wrong parts of the day . Modafinil is not a scheduled drug like the amphetamines and provided a much needed alternative. Modafinil has been tweaked to armodafinil (Nuvigil is the brand name, to be launched by Cephalon) to provide a longer course of action so that dosing once daily will allow someone to stay alert until it is time for them to get some zzzs when they desire. This will help those who suffer from jet lag, narcolepsy, obstructive sleep apnea, and shift work disorders.

Page : 11 to 2 of 2

Request a News Analysis

Subscribe to Updates

By RSS